SRI

Across TCGA pan-cancer cohorts, SRI mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRI data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SRI mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRI expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, UCEC, and LSCC are the cancer types where SRI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.500	0.764	<.001	36	view →
UCEC	OS	Median	II,III,IV	0.511	1.000	.002	30	view →
LSCC	OS	Median	III,IV	0.705	0.996	.021	8	view →
PDAC	DFS	Quartile	II,III,IV	0.979	0.675	.006	5	view →
CCRCC	DFS	Median	IV	0.749	0.253	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRI–HNSC (DFS)

Open the HNSC breakdown →